Gt biopharma to host interim gtb-3550 trike™ data review call with dr. jeffrey s. miller on may 19, 2021 at 4:00 pm et

Beverly hills, calif., may 18, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed natural killer (nk) cell engager immunotherapy protein biologic platform technology, trike™, for the treatment of cancer and infectious diseases, today announced that it will be hosting a call with dr. jeffrey s.
GTBP Ratings Summary
GTBP Quant Ranking